Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
Zillow (ZG)
Consensus Price Target: $74.26 (68.5% implied return)
Founded by Expedia co-founders Lloyd Frink and Rich Barton, Zillow (NASDAQ: ZG) is the leading U.S. online real estate marketplace.
Why Should You Dump ZG?
- Products and services aren't resonating with the market as its revenue declined by 5% annually over the last five years
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 10.6% for the last two years
- Rising returns on capital show management is making relatively better investments
Zillow’s stock price of $44.08 implies a valuation ratio of 20.2x forward P/E. Read our free research report to see why you should think twice about including ZG in your portfolio.
Semtech (SMTC)
Consensus Price Target: $104.62 (41.4% implied return)
A public company since the late 1960s, Semtech (NASDAQ: SMTC) is a provider of analog and mixed-signal semiconductors used for Internet of Things systems and cloud connectivity.
Why Are We Out on SMTC?
- Expenses have increased as a percentage of revenue over the last five years as its operating margin fell by 16.5 percentage points
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 7.6 percentage points
- Negative returns on capital show management lost money while trying to expand the business, and its decreasing returns suggest its historical profit centers are aging
Semtech is trading at $74.00 per share, or 35.6x forward P/E. Dive into our free research report to see why there are better opportunities than SMTC.
Artivion (AORT)
Consensus Price Target: $51.43 (45.6% implied return)
Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE: AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.
Why Do We Think Twice About AORT?
- Revenue base of $441.3 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Low free cash flow margin of -0.6% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
At $35.32 per share, Artivion trades at 45.1x forward P/E. To fully understand why you should be careful with AORT, check out our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
